Cure My Disease

Don't miss your cure!

 Log in / Sign up

Swiss launch national database to track rare lung disease

NCT ID NCT03606200

Recruiting now Knowledge-focused Sponsor: University of Bern Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is creating a national registry in Switzerland for people with primary ciliary dyskinesia (PCD), a rare lung condition. Researchers will collect information on symptoms, lung function, and treatments from up to 800 patients. The goal is to better understand the disease and support future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this registry could provide valuable data to better understand PCD and improve future treatments and care.
What could go wrong
This is an observational registry, not a treatment trial. It will not directly test any new therapy or intervention.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KARTAGENER SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary ciliary dyskinesia primary ciliary dyskinesia 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KARTAGENER SYNDROME PRIMARY CILIARY DYSKINESIA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Bern

    RECRUITING

    Bern, 3012, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.